Key result
High plasma vWf levels (≥158 IU/dL) added to the Birmingham clinical risk stratification scheme were independently associated with an increased risk of vascular events (HR 2.05; 95% CI 1.30-3.22).
Why the study?
Does the addition of plasma von Willebrand factor levels to clinical risk stratification schemes improve the prediction of ischemic stroke and vascular events in patients with atrial fibrillation?
Cohort (n=994)
Does the addition of plasma von Willebrand factor levels to clinical risk stratification schemes improve the prediction of ischemic stroke and vascular events in patients with atrial fibrillation?
Effect estimate: HR 2.05 (95% CI 1.30 to 3.22)
Elevated plasma von Willebrand factor levels (≥158 IU/dL) provide additive prognostic value to standard clinical risk scores (CHADS2, Birmingham) for predicting vascular events in patients with atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
vWf may refine vascular risk prediction beyond clinical scores in AF; hypothesis-generating and requires prospective validation before adoption.
Lip et al. (2006) conducted a cohort in Atrial Fibrillation (n=994). Plasma von Willebrand factor (vWf) levels vs. Clinical risk stratification schemes alone (Birmingham and CHADS2) was evaluated on Ischemic stroke and vascular events (HR 2.05, 95% CI 1.30 to 3.22). High plasma vWf levels (≥158 IU/dL) added to the Birmingham clinical risk stratification scheme were independently associated with an increased risk of vascular events (HR 2.05; 95% CI 1.30-3.22).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: